LexBlog IP

SEPTEMBER 14, 2023

The bill goes into effect on January 1, 2025, and a public outreach effort will begin by July 1, 2024. This week, Delaware Governor John Carney signed the Delaware Personal Data Privacy Act into law. The outreach effort will inform Delaware consumers of their rights under the new law and describe businesses’ obligations.

Privacy 52

Privacy Law Business Intellectual Property 52

The TTABlog

APRIL 11, 2024

Marty Schwimmer and yours truly, the TTABlogger , have decided to postpone our next MEET THE BLOGGERS get-together until next year. For some reason, I think it will be in Philadelphia. Does that ring a bell? In any event, we hope to see y'all in Atlanta next month.

Copyright 58

Copyright 58

JD Supra Law

APRIL 25, 2023

The USPTO has commenced the fee-setting process for fee adjustments it expects to implement in January 2025. By: Foley & Lardner LLP

Design Patent 52

Design Patent Patent Application Designs Design 52

Canadian Intellectual Property Blog

SEPTEMBER 21, 2023

If you sell products or have public signage in the Province of Québec, then please consider what changes, if any, will be necessary to the product inscriptions/packaging and signage to ensure compliance with the amendments to the Charter of the French Language, c-11, which will come into force on June 1, 2025.

Intellectual Property Law 52

Intellectual Property Law Intellectual Property Business Litigation 52

IP Close Up

APRIL 9, 2024

Thanks in part to data-hungry artificial intelligence and growing anger over foreign and domestic intellectual property abuses, fixing the IP system is more topical than Continue reading

Intellectual Property 87

Intellectual Property IP Government Trademark 87

McKinsey Operations

JULY 8, 2022

What will drive China’s next wave of cloud adoption? Successful enterprises will focus not on moving to the cloud but on using it to deliver tangible business value.

Business 81

Business 81

JD Supra Law

OCTOBER 23, 2023

By 2025, various online sources estimate. Slack, a collaboration tool for workplaces, has been among the forces upending the established communication order, offering an organized alternative to email. By: Array

Reporting 115

Reporting 115

JD Supra Law

OCTOBER 25, 2023

In 2025, the National Aeronautics and Space Administration (NASA) is scheduled to once again bring man and machine to the lunar surface, this time under the name of the Greek goddess Artemis. However, the means to the ends have changed.

Invention 116

Invention Patent 116

LexBlog IP

DECEMBER 13, 2023

Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA® If SB17 is approved by the FDA, the license period in the United States will begin on February (..)

Litigation 52

Litigation Settlement Licensing Marketing 52

JD Supra Law

MARCH 7, 2024

by February 2025, subject to FDA approval. The parties announced in a press release that their settlement and license agreement allows Biocon to commercialize Bmab 1200, its proposed biosimilar to Stelara® (ustekinumab), in the U.S. By: Venable LLP

Settlement 67

Settlement Licensing 67

JD Supra Law

FEBRUARY 15, 2024

Bayer has a second patent that is subject to a pediatric exclusivity that expires later - February 2025 - and Mylan concedes that the second patent blocks approval for its generic version of Xarelto® until that time. Bayer's ‘053 patent on its drug Xarelto® expires in November 2024, and Bayer granted Mylan a covenant not to sue.

Patent 69

Patent 69

JD Supra Law

MARCH 25, 2024

Goldman Sachs reported AI investment was forecast to approach $200 billion globally by 2025, and 47% of top technology officers (e.g. What began as cocktail hour conversations and funny experiments quickly made its way into boardrooms and budgets. CIO, CTO) reported to CNBC that AI was their number one budget item in 2024.

Intellectual Property 61

Intellectual Property Reporting Technology 61

JD Supra Law

JULY 24, 2023

Established through the Charter of the French Language, French is the official language of the Province of Québec. The Charter applies to businesses located in Québec and to other businesses providing services and selling goods in this province, making the use of French mandatory in connection with these business activities.

Business 52

Business 52

LexBlog IP

FEBRUARY 7, 2024

Amendments to the Charter are expected to come into force on June 1, 2025. As of June 1, 2025, unless a trademark appearing on a product, on a storefront or in commercial advertising is registered in Canada, a French version of that mark will have to appear. Fines for second offences are doubled and thereafter tripled.

Registering Trademarks 52

Registering Trademarks Advertising Advertising Social Media 52

Olartemoure Blog

FEBRUARY 8, 2024

This year, it begins on February 10th 2024 , and finishes on 29th of January 2025 , marking the start of the Year of the Snake. Variable dates of the chinese new year: The start of the Chinese New Year varies each year due to its adherence to the lunar calendar.

Intellectual Property 116

Intellectual Property IP 116

JD Supra Law

FEBRUARY 19, 2024

For example, it is estimated that by 2025, more than 26 billion home and workplace devices will be connected to the Internet and have sensors, processors, and embedded software for facilitating connectivity. By: Sterne, Kessler, Goldstein & Fox P.L.L.C.

Patent 61

Patent 61

JD Supra Law

MARCH 28, 2022

It is estimated that by 2025, more than 26 billion home and workplace devices will be connected to the internet and have embedded software or sensors. The economic impact of these “connected” devices is estimated to be approximately $10 trillion per year by 2025. It is no surprise then that in the last.

Patent 98

Patent Litigation 98

JD Supra Law

DECEMBER 13, 2023

If SB17 is approved by the FDA, the license period in the United States will begin on February 22, 2025. Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA®.

Litigation 67

Litigation Settlement Licensing Reporting 67

JD Supra Law

JANUARY 18, 2024

Amendments to the Charter of French Language (Charter) scheduled to come into force on June 1, 2025 will have major implications on trademark owners doing business in Quebec, Canada. This doesn’t just impact Canadian companies, but also the many U.S. companies doing business in Canada.

Trademark 69

Trademark Business 69

Michael Geist

AUGUST 25, 2023

The proposed timeline has taken many by surprise as it suggests that mandatory bargaining may not begin until 2025. Certifying “eligible news businesses” and confirming arbitrators could take the process into early 2025, at which time the mandatory bargaining process can begin.

Government 98

Government Business Law Reporting 98

JD Supra Law

APRIL 4, 2024

On March 26, 2024, the US Patent & Trademark Office (PTO) issued a notice of proposed rulemaking in the Federal Register concerning changes to trademark application filings and fee adjustments in trademark cases for 2025. The PTO solicits written comments from the public on the proposed rule changes on or before May 28, 2024.

Trademark 47

Trademark Patent 47

The IP Law Blog

MARCH 5, 2024

Deadlines to File Your BOI Report: Entity Type BOI Filing Deadline Entities in Existence Prior to January 1, 2024 On or before January 1, 2025 Entities Formed on or after January 1, 2024 90 days from the date of formation Entities Formed on or after January 1, 2025 30 days from the date of formation Resources: Corporate Transparency Act Resource Hub (..)

Reporting 57

Reporting Business Intellectual Property Litigation 57

LexBlog IP

MARCH 6, 2024

The agreement allows Biocon to launch in the United States in February 2025, pending FDA approval. entry date for its ustekinumab biosimilar, WEZLANA, of January 1, 2025, and in October 2023, the FDA approved WEZLANA as biosimilar to and interchangeable with STELARA. Amgen secured a U.S.

Marketing 52

Marketing Marketing Settlement Licensing 52

JD Supra Law

AUGUST 31, 2023

market on March 7, 2025, if approved by FDA. It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. By: Goodwin

Settlement 72

Settlement Reporting Marketing Marketing 72

LexBlog IP

SEPTEMBER 27, 2023

The parties will file dispositive motions on June 4, 2025, with responsive and reply briefing complete by July 2, 2025, and July 25, 2025, respectively. The Court further scheduled a five-day jury trial to begin on November 17, 2025. Stay tuned to Big Molecule Watch for more updates on this litigation.

Litigation 52

Litigation Reporting Patent Intellectual Property 52

LexBlog IP

JUNE 13, 2023

. “According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025.” The post Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J appeared first on Big Molecule Watch.

Settlement 52

Settlement Marketing Marketing Licensing 52

IP Law 360

APRIL 26, 2023

Patent and Trademark Office has proposed numerous patent fee increases that would take effect in 2025 if adopted, including notable hikes related to continuing applications, design patents and post-grant challenges that attorneys say could alter applicant behavior.

Patent 75

Patent Design Patent Designs Design 75

LexBlog IP

MARCH 6, 2024

Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. In March 2023, Health Canada granted tentative approval for YESAFILI 2 mg vials, subject to resolution of any patent disputes. Extensive cover of U.S.

Marketing 52

Marketing Marketing Settlement Litigation 52

IP Law 360

NOVEMBER 1, 2023

1, 2025, the firm announced Wednesday. DLA Piper Americas Chair Frank Ryan has been elected to a second four-year term starting Jan.

52

52

LexBlog IP

AUGUST 16, 2023

The settlement permits marketing of FYB202 in the United States, subject to regulatory approval, no later than April 15, 2025. According to the press release, Formycon plans to submit a biologics license application later in 2023 to seek regulatory approval for FBY202. Economic terms of the settlement were not disclosed in the press release.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

The IPKat

NOVEMBER 24, 2023

ELSA Scholarship 2024-2025 Applications for the European Law Students' Association (ELSA) Scholarship 2024-2025 are now open. As part of this review, the IPO is asking businesses to share their views by taking part in a short survey, available here. The survey should take about 10-15 mins to complete and closes on 2 February 2024.

Intellectual Property 67

Intellectual Property IP Music Designs 67

LexBlog IP

AUGUST 30, 2023

market on March 7, 2025, if approved by FDA. It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S.

Settlement 52

Settlement Confidentiality Marketing Marketing 52

LexBlog IP

MARCH 5, 2024

Deadlines to File Your BOI Report: Entity Type BOI Filing Deadline Entities in Existence Prior to January 1, 2024 On or before January 1, 2025 Entities Formed on or after January 1, 2024 90 days from the date of formation Entities Formed on or after January 1, 2025 30 days from the date of formation Resources: Corporate Transparency Act Resource Hub (..)

Reporting 40

Reporting Business Intellectual Property 40

IAM Magazine

SEPTEMBER 23, 2021

A new high-level policy calls for growth by a metric that includes not just royalty receipts but also payments to foreign IP owners.

IP 52

IP Licensing Marketing Marketing 52

WIPO Magazine

NOVEMBER 5, 2023

trillion by 2025, crippling businesses and critical infrastructure. The cost of cybercrime set to rise to USD 10.5

IP 52

IP Business 52

JD Supra Law

APRIL 28, 2023

The USPTO has indicated that the fee proposal is expected to be implemented around January 2025. Patent and Trademark Office (USPTO) has proposed a significant increase in patent fees, including the implementation of entirely new fees and revamped fee structures. By: Fox Rothschild LLP

Patent 52

Patent Trademark 52

JD Supra Law

AUGUST 3, 2023

Notably, since our last update, Janssen and Amgen reached a settlement allowing for the launch of Amgen’s biosimilar to Stelara no later than January 1, 2025. Since the enactment of the Biologics Price Competition and Innovation Act (BPCIA), 41 biosimilars have been approved, 22 of which have launched. By: Morgan Lewis

Settlement 52

Settlement Litigation Patent 52